دورية أكاديمية
أعرض في EDS

A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma.

التفاصيل البيبلوغرافية
العنوان: A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma.
المؤلفون: Prather KY; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., O'Neal CM; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Westrup AM; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Tullos HJ; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Hughes KL; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Conner AK; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Glenn CA; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA., Battiste JD; Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
المصدر: Neuro-oncology advances [Neurooncol Adv] 2022 Feb 13; Vol. 4 (1), pp. vdac008. Date of Electronic Publication: 2022 Feb 13 (Print Publication: 2022).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Oxford] : Oxford University Press, [2019]-
مستخلص: The response assessment in neuro-oncology (RANO) criteria have been the gold standard for monitoring treatment response in glioblastoma (GBM) and differentiating tumor progression from pseudoprogression. While the RANO criteria have played a key role in detecting early tumor progression, their ability to identify pseudoprogression is limited by post-treatment damage to the blood-brain barrier (BBB), which often leads to contrast enhancement on MRI and correlates poorly to tumor status. Amino acid positron emission tomography (AA PET) is a rapidly growing imaging modality in neuro-oncology. While contrast-enhanced MRI relies on leaky vascularity or a compromised BBB for delivery of contrast agents, amino acid tracers can cross the BBB, making AA PET particularly well-suited for monitoring treatment response and diagnosing pseudoprogression. The authors performed a systematic review of PubMed, MEDLINE, and Embase through December 2021 with the search terms "temozolomide" OR "Temodar," "glioma" OR "glioblastoma," "PET," and "amino acid." There were 19 studies meeting inclusion criteria. Thirteen studies utilized [ 18 F]FET, five utilized [ 11 C]MET, and one utilized both. All studies used static AA PET parameters to evaluate TMZ treatment in glioma patients, with nine using dynamic tracer parameters in addition. Throughout these studies, AA PET demonstrated utility in TMZ treatment monitoring and predicting patient survival.
(© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
References: Neurology. 2015 Feb 17;84(7):710-9. (PMID: 25609769)
J Neurooncol. 2018 Sep;139(3):721-730. (PMID: 29948765)
Nucl Med Commun. 2019 Aug;40(8):850-856. (PMID: 31135693)
J Nucl Med. 2012 Jul;53(7):1048-57. (PMID: 22645298)
Clin Cancer Res. 2006 Aug 1;12(15):4738-46. (PMID: 16899625)
Eur J Nucl Med Mol Imaging. 2006 May;33(5):516-24. (PMID: 16450140)
Bioengineering (Basel). 2018 Nov 28;5(4):. (PMID: 30487391)
ISRN Oncol. 2014 Feb 04;2014:463152. (PMID: 24649372)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):593-601. (PMID: 29282517)
Neuroimaging Clin N Am. 2002 Nov;12(4):615-26. (PMID: 12687915)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
J Neurooncol. 2009 Oct;95(1):87-93. (PMID: 19381442)
World Neurosurg. 2018 Nov;119:e653-e660. (PMID: 30077752)
Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95. (PMID: 25411133)
Clin Neuroradiol. 2018 Sep;28(3):401-411. (PMID: 28466127)
N Engl J Med. 2005 Mar 10;352(10):997-1003. (PMID: 15758010)
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1049-58. (PMID: 21570201)
Cancers (Basel). 2020 Dec 18;12(12):. (PMID: 33353180)
Front Neurol. 2016 Jul 28;7:120. (PMID: 27516754)
Br J Radiol. 2018 Apr;91(1084):20170847. (PMID: 29271230)
Radiother Oncol. 2012 Jul;104(1):78-82. (PMID: 22673727)
Cancers (Basel). 2020 Oct 22;12(11):. (PMID: 33105661)
Mol Imaging. 2013 Sep;12(6):388-95. (PMID: 23981784)
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1889-1901. (PMID: 31203420)
Neurology. 2007 Feb 27;68(9):688-90. (PMID: 17325277)
Neuro Oncol. 2019 Jul 11;21(7):837-853. (PMID: 30753579)
J Clin Oncol. 2012 Jul 20;30(21):e180-3. (PMID: 22689800)
Mol Imaging. 2010 Feb;9(1):40-6. (PMID: 20128997)
Hong Kong Med J. 2017 Dec;23(6):594-8. (PMID: 28798282)
Nat Rev Neurol. 2017 May;13(5):279-289. (PMID: 28387340)
World Neurosurg. 2019 May;125:93-100. (PMID: 30716494)
J Nucl Med. 2021 Jul 1;62(7):918-925. (PMID: 33158907)
Mol Imaging. 2014;13:. (PMID: 24825818)
Neuroimage Clin. 2017 Nov 08;17:491-497. (PMID: 29159062)
CNS Oncol. 2019 Mar 1;8(1):CNS28. (PMID: 30806082)
Surg Neurol. 2009 Oct;72(4):423-8. (PMID: 19150114)
Eur J Nucl Med Mol Imaging. 2015 May;42(6):905-15. (PMID: 25750084)
J Neurooncol. 2012 May;108(1):173-7. (PMID: 22382781)
J Clin Oncol. 2010 Apr 10;28(11):1963-72. (PMID: 20231676)
Oncology (Williston Park). 2018 Nov 15;32(11):555-60, 569. (PMID: 30474103)
Neuro Oncol. 2016 May;18(5):744-51. (PMID: 26578622)
Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):176-84. (PMID: 20646863)
Methods. 2017 Nov 1;130:124-134. (PMID: 28552264)
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1115-23. (PMID: 26646781)
Clin Cancer Res. 2021 Jul 1;27(13):3704-3713. (PMID: 33947699)
Sci Rep. 2019 Nov 28;9(1):17794. (PMID: 31780768)
Oncol Rev. 2020 Feb 18;14(1):461. (PMID: 32153727)
Clin Cancer Res. 2016 May 1;22(9):2190-6. (PMID: 26673798)
فهرسة مساهمة: Keywords: amino acid PET; glioblastoma; glioma; pseudoprogression; temozolomide; treatment response
تواريخ الأحداث: Date Created: 20220318 Latest Revision: 20220319
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8923003
DOI: 10.1093/noajnl/vdac008
PMID: 35300149
قاعدة البيانات: MEDLINE
الوصف
تدمد:2632-2498
DOI:10.1093/noajnl/vdac008